Trends of Carbapenem-Resistant Gram-negative Bacteria in China: A Surveillance Study Between 2015 and 2024
The Journal of Infectious Diseases · 13.03.2026 · 233 (Supplement_1) · S113-S117
DOI: 10.1093/infdis/jiag083 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 10.03.2026. Verfasst von Yan Guo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Carbapenems, Anti-Bacterial Agents, Gram-Negative Bacteria, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: China Antimicrobial Surveillance Network, Pfizer, Shanghai Antimicrobial Surveillance Network.
Abstract (Originalsprache)
Objective
To monitor the trends of carbapenem-resistant gram-negative bacteria to antimicrobial agents in healthcare facilities in major regions of China between 2015 and 2024.
Methods
Carbapenem-resistant gram-negative isolates from 74 hospitals in the country were tested for antimicrobial susceptibility using an automated method (imported or domestic AST instruments) supplemented by the disc diffusion method. Results were evaluated using the 2024 CLSI breakpoint.
Results
A total of 339 513 clinical isolates were collected between 2015 and 2024. Among clinical Enterobacterales isolates, the rate of carbapenem resistance was generally below 13%, except for Klebsiella spp., where it ranged from 20.4% to 21.9%. Most clinical Enterobacterales isolates are highly susceptible to tigecycline, colistin, and polymyxin B, with resistance rates ranging from 0.1% to 15.4%. The detection rate of meropenem-resistant Pseudomonas aeruginosa has decreased over six consecutive years, from 31.4% in 2018 to 21.5% in 2024. The detection rate of meropenem-resistant Acinetobacter baumannii remained modest, from 64.9% in 2015 to 68.3% in 2024.
Conclusions
Multidrug-resistant bacteria remain a significant challenge in clinical anti-infective treatment, and the surveillance of bacterial resistance and the rational use of antimicrobial agents need to be further strengthened to combat bacterial resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
- Key Laboratory of Clinical Pharmacology of Antibiotics, Ministry of Health, Shanghai, China.
- Joint Laboratory of Hospital & Enterprise for Pathogen Diagnosis of Drug-Resistant Bacterial Infections and Innovative Drug R&D, Shanghai, China.
- Medical Laboratory, Tengchong People's Hospital, Yunnan, China.
ORCID-Profile: Li Ding
Förderung
- China Antimicrobial Surveillance Network
- Pfizer
- Shanghai Antimicrobial Surveillance Network
Zitieren
APA
Guo, Y., Ding, L., Zhou, Y., Ren, X., Han, R., Yin, D., Wu, S., Yang, Y., Shen, S., Zhu, D., & Hu, F. (2026). Trends of Carbapenem-Resistant Gram-negative Bacteria in China: A Surveillance Study Between 2015 and 2024. The Journal of Infectious Diseases, 233(Supplement_1), S113-S117. https://doi.org/10.1093/infdis/jiag083
Vancouver
Guo Y, Ding L, Zhou Y, Ren X, Han R, Yin D, et al. Trends of Carbapenem-Resistant Gram-negative Bacteria in China: A Surveillance Study Between 2015 and 2024. The Journal of Infectious Diseases. 2026;233(Supplement_1):S113-S117. doi:10.1093/infdis/jiag083
BibTeX
@article{Guo2026,
author = {Guo, Yan and Ding, Li and Zhou, Yanhao and Ren, Xiaoyan and Han, Renru and Yin, Dandan and Wu, Shi and Yang, Yang and Shen, Siquan and Zhu, Demei and Hu, Fupin},
title = {Trends of Carbapenem-Resistant Gram-negative Bacteria in China: A Surveillance Study Between 2015 and 2024},
journal = {The Journal of Infectious Diseases},
year = {2026},
volume = {233},
number = {Supplement_1},
pages = {S113--S117},
doi = {10.1093/infdis/jiag083}
}
EUVIMED